Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.
NoviSci is a software analytics and services company focused on enhancing population health outcomes, particularly for vulnerable patients with complex health conditions. The company leverages principled data science to develop tools that visualize and analyze health data through modern epidemiological methods. By employing sound scientific principles, NoviSci aims to improve the health and well-being of individuals, addressing the specific needs of populations that may be at higher risk.
Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing ocular gene therapies aimed at reversing or preventing blindness. The company focuses on treating prominent forms of Leber congenital amaurosis and Usher syndrome. Utilizing adeno-associated virus technology, Atsena's pipeline is designed to address the challenges associated with inherited retinal diseases, providing innovative solutions to restore vision and improve the quality of life for patients affected by these conditions.
Altis Biosystems, LLC is a biotechnology company that specializes in developing stem cell technologies aimed at enhancing research in human biology. Founded in 2015 and located in Chapel Hill, North Carolina, the company has created the RepliGut system, which utilizes a patent-pending technology to recreate the human intestinal epithelium. This system produces layers of human or animal intestinal stem and differentiated cells from both the small and large intestines. Altis Biosystems' products are primarily used in preclinical studies for disease modeling, microbiome research, and compound screening. By enabling the use of normal human intestinal tissue, their technology helps scientists develop safer and more effective drugs while minimizing reliance on animal testing.
Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing ocular gene therapies aimed at reversing or preventing blindness. The company focuses on treating prominent forms of Leber congenital amaurosis and Usher syndrome. Utilizing adeno-associated virus technology, Atsena's pipeline is designed to address the challenges associated with inherited retinal diseases, providing innovative solutions to restore vision and improve the quality of life for patients affected by these conditions.
410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.
WalletFi is a developer of a subscription management platform that helps users manage recurring charges and payments. The platform utilizes machine learning technology to identify subscriptions and Card-on-File merchants, providing personalized insights to users. By facilitating the transfer of payments to new cards during re-issuance, WalletFi not only aids consumers in managing their financial commitments but also reduces customer churn for banks and financial institutions. This approach enhances customer engagement and reinforces the loyalty of users towards their financial service providers. Additionally, WalletFi offers detailed analytics that enable financial institutions to expand their customer base and improve overall user wellness, ultimately delivering a measurable return on investment.
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.
Mati Inc. is a company based in Durham, North Carolina, that specializes in the production and sale of energy drinks. Founded in 2012, it offers a unique energy drink brewed from plant-based ingredients, fruit juice concentrates, and water. The flagship product, MATI, is designed to provide a healthier alternative for active and health-conscious consumers seeking to enhance their everyday performance. Mati Inc. distributes its products through various channels, including wholesalers, retail outlets, and online platforms, primarily serving customers in North Carolina and surrounding counties. As of April 2020, Mati Inc. operates as a subsidiary of NOBL Beverages.
NeuroTronik
Series B in 2017
NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,
Bivarus, Inc. is a company based in Durham, North Carolina, specializing in a cloud-based analytics platform designed to enhance continuous quality improvement (CQI) and the patient experience within hospital-based outpatient services, community clinics, and group practices. Founded in 2010, Bivarus emerged from academic research that highlighted the significance of patient experience as a predictor of health outcomes. The platform provides healthcare leaders with actionable insights into the factors influencing patient experience, provider performance, and service operations, enabling real-time identification of service issues and evaluation of quality improvement initiatives. Bivarus is recognized as a CMS-approved CAHPS® partner and also offers services for assessing employee perceptions related to organizational effectiveness, culture, and safety, thereby supporting engagement across healthcare organizations. As of January 2018, Bivarus operates as a subsidiary of Press Ganey Holdings, Inc.
Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Bivarus, Inc. is a company based in Durham, North Carolina, specializing in a cloud-based analytics platform designed to enhance continuous quality improvement (CQI) and the patient experience within hospital-based outpatient services, community clinics, and group practices. Founded in 2010, Bivarus emerged from academic research that highlighted the significance of patient experience as a predictor of health outcomes. The platform provides healthcare leaders with actionable insights into the factors influencing patient experience, provider performance, and service operations, enabling real-time identification of service issues and evaluation of quality improvement initiatives. Bivarus is recognized as a CMS-approved CAHPS® partner and also offers services for assessing employee perceptions related to organizational effectiveness, culture, and safety, thereby supporting engagement across healthcare organizations. As of January 2018, Bivarus operates as a subsidiary of Press Ganey Holdings, Inc.
Medfusion, Inc. operates a patient engagement portal aimed at enhancing healthcare services for providers and patients in the United States and internationally. The platform facilitates communication through various clinical, administrative, and financial services, including billing solutions such as online bill pay and payment plans, as well as secure patient messaging and prescription renewal requests. Medfusion also offers front desk solutions like appointment requests and patient registration, along with mobile applications that empower patients to access their health data. Additional services include EHR/PM integration and Practice Intelligence, which provides insights into patient communication traffic. Founded in 1996 and based in Cary, North Carolina, Medfusion originally focused on medical website development for healthcare clients, evolving to meet the specific needs of the healthcare sector.
Spyryx Biosciences is a biopharmaceutical company based in Durham, North Carolina, specializing in the development of inhaled peptide therapeutics aimed at treating obstructive lung diseases, specifically cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Founded in 2013 by Dr. Robert Tarran, the company emerged from his discovery of a novel mechanism by which the lungs regulate surface fluid. This mechanism is impaired in CF patients due to genetic mutations, leading to dehydration, mucus buildup, and subsequent lung damage. Spyryx's therapeutic approach targets this underlying dysfunction, showing promising results in preclinical studies by significantly improving survival in animal models of CF. Importantly, the treatment is designed to function independently of the specific genetic mutations responsible for CF, offering potential benefits to a broader patient population. Additionally, the company is exploring the relevance of this fluid regulation mechanism in COPD, a condition characterized by chronic bronchitis and emphysema, as part of its commitment to addressing multiple obstructive lung diseases.
Contego Medical, Inc. develops emboli protection devices that are used for the treatment of cardiovascular and endovascular diseases. It offers angioplasty balloons and stent delivery catheters, such as coronary stent systems, carotid post-dilation balloons, and renal artery stent systems with integrated embolic protection devices for enabling carotid, renal, SVG, and coronary interventions. Contego Medical, Inc. was formerly known as Contego Medical, LLC. The company was founded in 2005 and is based in Raleigh, North Carolina with an additional office in Curitiba, Brazil.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Private Equity Round in 2015
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Clinverse is a technology company solely focused on the financial management of clinical trials and associated payments in over 140 currencies. Our flagship product, ClinPay, is a secure on-line eClinical Trial Payment Network that dramatically reduces time spent on the investigator payment process with significant increases in clinical trial productivity. ClinPay links sponsors to investigators in a payment and reporting system that reduces study start-up time, makes possible timely and accurate payments, provides transparency and auditing records, and simplifies compliance.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
ArtusLabs is developing and deploying Web 2.0 enabled software platforms that enable groups of scientists, and thereby individual scientists, to deliver significantly better (and more) business value to their shareholders, faster. ArtusLabs was founded by the same proven team that formed Synthematix, the award winning organization that pioneered the Enterprise Electronic Lab Notebook marketplace. This leadership and development team has extensive expertise in processing, mining and managing complex scientific data and information generated from research activities. With a wealth of experience and very close relationships with scientists around the globe, the team at ArtusLabs continues to build the best collaborative customer experience and technologies for researchers -- hands down.
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Empliant, Inc., located in Chapel Hill, N.C., provides web-native, employee self-reliant data collection solutions. Online benefits enrollment reduces administrative costs, increases employee satisfaction, and enhances operational efficiency. Their technology applications include on-line benefits enrollment and administration and personalized employee benefits statements. They also deliver a fully searchable content management knowledgebase for benefit plan information, company policies, or management practices. Their Software as a Service (SaaS) solution eliminates up front costs and enables employers to provide employees with self-service capabilities for pennies a day per employee. Empliant offers small to medium-sized enterprises (SME) the rich functionality found in expensive applications without the consulting costs, long implementation period, and reliance on customer support and product maintenance.